非小细胞肺癌患者血清中miRNA-449a的表达及其临床意义

Expression of miRNA-449a in serum and its clinical significance in patients with non-small cell lung cancer

目的探讨miRNA-449a在非小细胞肺癌患者血清中的表达及其临床应用价值。方法采用荧光定量PCR法检测26例非小细胞肺癌患者和30例健康人群血清中miRNA-449a的表达含量,分析血清miRNA-449a的含量与非小细胞肺癌患者临床病理特征的关系,并通过受试者工作曲线(ROC)分析miRNA-449a在非小细胞肺癌诊断中的特异性和敏感性。结果非小细胞肺癌患者血清中miRNA-449a的含量显著低于健康人群(P<0.05);非小细胞肺癌血清中miRNA-449a的表达与肿瘤TNM分期以及淋巴结转移有相关性(P<0.05),与病理组织学类型无相关性(P>0.05)。ROC曲线下面积(AUC)为0.840(95%CI 0.693-0.986),取0.624作为其临界值时,其敏感性和特异性分别为77.8%和84.6%。结论 miRNA-449a在非小细胞肺癌血清中低表达,并可能成为非小细胞肺癌患者诊断的肿瘤标志物之一。

Objective To investigate the expression of miRNA-449 a in serum of patients with non-small cell lung cancer and its clinical significance. Methods The quantitative real-time PCR was used to detect the expression of miRNA-449 a in 26 non-small cell lung cancer patients and 30 healthy controls. The relationship between the serum of serum miRNA-449 a and clinical pathological parameters was analyzed. The specificity and sensitivity of miRNA-449 a in the diagnosis of non-small cell lung cancer was determined by receiver-operating characteristic( ROC) curves. Results The expression of miRNA-449 a in non-small cell lung cancer was significantly lower than that of healthy controls( P < 0. 05). The expression of miRNA-449 a was significantly associated with the tumor clinical stage( TNM) and lymphatic metastasis( P < 0. 05),and the expression of miRNA-449 a was not significantly associated with the histological type( P > 0. 05). The area under ROC was 0. 840( 95% CI 0. 693-0. 986),and the sensitivity and specificity were 77. 8%and 84. 6% when 0. 513 was selected as the critical value. Conclusion The expression of serum miRNA-449 a is significantly reduced in patients with non-small cell lung cancer cell,and it may be a biomarker for the clinical diagnosis of non-small cell lung cancer.